Base de dados : MEDLINE
Pesquisa : D09.408.051.476.600 [Categoria DeCS]
Referências encontradas : 142 [refinar]
Mostrando: 1 .. 10   no formato [Detalhado]

página 1 de 15 ir para página                         

  1 / 142 MEDLINE  
              next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28426744
[Au] Autor:Dai C; Zhao T; Yang X; Xiao X; Velkov T; Tang S
[Ad] Endereço:Department of Pharmacology and Toxicology, College of Veterinary Medicine, China Agricultural University, Beijing, P. R. China.
[Ti] Título:Pharmacokinetics and relative bioavailability of an oral amoxicillin-apramycin combination in pigs.
[So] Source:PLoS One;12(4):e0176149, 2017.
[Is] ISSN:1932-6203
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:A new compound granular premix of amoxicillin (20% w/w dry mass)/apramycin (5% w/w dry mass) was developed, and its pharmacokinetics and relative bioavailability were determined in pigs following oral administration following a cross-over study design. The pharmacokinetic parameters of amoxicillin (t1/2λ = 6.43 ± 4.85h, Cmax = 3.2 ± 1.35 µg·mL-1, Tmax = 1.92 ± 0.58, AUCINF = 8.98 ± 2.11 h·µg·mL-1) and apramycin (t1/2λ = 8.67±4.4h, Cmax = 0.23 ± 0.12 µg·mL-1, Tmax = 2.25 ± 0.82 h, AUCINF = 12.37 ± 8.64h·µg·mL-1) when administered as the amoxicillin-apramycin granular premix did not significantly differ from those for the single-ingredient powder form of each component. The relative bioavailability of amoxicillin following oral administration of the amoxicillin-apramycin granular premix was 22.62% when compared to the intramuscular administration of commercial amoxicillin sodium-powder. This is the first report of a new amoxicillin-apramycin combination which has a potential veterinary application the for prevention and treatment digestive tract infections in pigs.
[Mh] Termos MeSH primário: Amoxicilina/farmacocinética
Nebramicina/análogos & derivados
[Mh] Termos MeSH secundário: Administração Oral
Amoxicilina/administração & dosagem
Animais
Área Sob a Curva
Disponibilidade Biológica
Cromatografia Líquida de Alta Pressão
Estudos Cross-Over
Nebramicina/administração & dosagem
Nebramicina/farmacocinética
Suínos
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
11048-13-8 (Nebramycin); 388K3TR36Z (apramycin); 804826J2HU (Amoxicillin)
[Em] Mês de entrada:1709
[Cu] Atualização por classe:170907
[Lr] Data última revisão:
170907
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170421
[St] Status:MEDLINE
[do] DOI:10.1371/journal.pone.0176149


  2 / 142 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28034758
[Au] Autor:Kim M; Kim M; Kim KS
[Ad] Endereço:Department of Chemistry and Chemistry Institute of Functional Materials, Pusan National University, Busan, 46241, South Korea.
[Ti] Título:YmdB-mediated down-regulation of sucA inhibits biofilm formation and induces apramycin susceptibility in Escherichia coli.
[So] Source:Biochem Biophys Res Commun;483(1):252-257, 2017 Jan 29.
[Is] ISSN:1090-2104
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:Antibiotic resistance associated with biofilm formation is a major concern when treating bacterial infections with drugs. The genes and pathways involved in biofilm formation have been extensively studied and are also involved in antibiotic resistance. Recent studies show that overexpression of Escherichia coli (E. coli) YmdB protein alters gene expression profiles and inhibits biofilm formation. Therefore, it is expected that YmdB and its regulated genes play a key role in development of biofilm and antibiotic resistance phenotypes. The present study screened antibiotics to identify those whose susceptibility profiles were regulated by YmdB levels. This protocol identified apramycin. Additional screening for genes negatively regulated by inactivation of RNase III activity via YmdB overexpression revealed that a gene associated with the tricarboxylic acid cycle gene, sucA, was necessary for the YmdB-like phenotype. Taken together, these data suggest that regulation of RNase III activity by trans-acting factors may be the key to identifying genes or pathways connecting biofilm and antibiotic resistance phenotypes. This information could be used to reduce the emergence of biofilm-associated multidrug-resistant bacteria.
[Mh] Termos MeSH primário: Proteínas de Transporte/metabolismo
Proteínas de Escherichia coli/metabolismo
Escherichia coli/fisiologia
Complexo Cetoglutarato Desidrogenase/metabolismo
Nebramicina/análogos & derivados
[Mh] Termos MeSH secundário: Biofilmes/crescimento & desenvolvimento
Proteínas de Transporte/genética
Regulação para Baixo
Resistência Microbiana a Medicamentos/efeitos dos fármacos
Resistência Microbiana a Medicamentos/genética
Escherichia coli/efeitos dos fármacos
Proteínas de Escherichia coli/genética
Regulação Bacteriana da Expressão Gênica/efeitos dos fármacos
Complexo Cetoglutarato Desidrogenase/genética
Testes de Sensibilidade Microbiana
Nebramicina/farmacologia
Ribonuclease III/genética
Ribonuclease III/metabolismo
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Carrier Proteins); 0 (Escherichia coli Proteins); 0 (YmdB protein, E coli); 11048-13-8 (Nebramycin); 388K3TR36Z (apramycin); EC 1.2.4.2 (Ketoglutarate Dehydrogenase Complex); EC 1.2.4.2 (sucB protein, E coli); EC 3.1.26.3 (Ribonuclease III)
[Em] Mês de entrada:1706
[Cu] Atualização por classe:170601
[Lr] Data última revisão:
170601
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:161231
[St] Status:MEDLINE


  3 / 142 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:27599765
[Au] Autor:Kudo F; Tokumitsu T; Eguchi T
[Ad] Endereço:Department of Chemistry, Tokyo Institute of Technology, Tokyo, Japan.
[Ti] Título:Substrate specificity of radical S-adenosyl-l-methionine dehydratase AprD4 and its partner reductase AprD3 in the C3'-deoxygenation of aminoglycoside antibiotics.
[So] Source:J Antibiot (Tokyo);70(4):423-428, 2017 Apr.
[Is] ISSN:0021-8820
[Cp] País de publicação:Japan
[La] Idioma:eng
[Ab] Resumo:A radical S-adenosyl-l-methionine dehydratase AprD4 and an NADPH-dependent reductase AprD3 are responsible for the C3'-deoxygenation of pseudodisaccharide paromamine in the biosynthesis of apramycin. These enzymes are involved in the construction of the characteristic structural motif that is not modified by 3'-phosphotransferase in aminoglycoside-resistant bacterial strains. AprD4 catalyzes the C3'-dehydration of paromamine via a radical-mediated reaction mechanism to give 4'-oxolividamine, which is then reduced by AprD3 with NADPH to afford lividamine. In the present study, the substrate specificity of this unique combination of enzymes has been investigated. AprD4 was found to recognize paromamine, neamine, kanamycin C, and kanamycin B to afford 5'-deoxyadenosine as one of products during the C3'-dehydration of aminoglycosides, but not 2'-N-acetylparomamine and paromomycin. Only paromamine and kanamycin C were converted to the corresponding C3'-deoxygenated compounds by AprD4 and AprD3. AprD3 recognizes the 4'-oxolividamine moiety, including the pseudotrisaccharide kanamycin C, and seems to reject the amino group at C6' of neamine and kanamycin B. Chirally deuterium-labeled NADPH was used to identify that that AprD3 transfers the pro-S hydrogen atom of NADPH when reducing 4'-oxolividamine to give lividamine.
[Mh] Termos MeSH primário: Actinobacteria/enzimologia
Aminoglicosídeos/metabolismo
Antibacterianos/metabolismo
Hidroliases/metabolismo
[Mh] Termos MeSH secundário: Canamicina/análogos & derivados
NADP/metabolismo
Nebramicina/análogos & derivados
Especificidade por Substrato
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Aminoglycosides); 0 (Anti-Bacterial Agents); 11048-13-8 (Nebramycin); 15JT14C3GI (bekanamycin); 388K3TR36Z (apramycin); 53-59-8 (NADP); 534-47-4 (paromamine); 59-01-8 (Kanamycin); EC 4.2.1.- (Hydro-Lyases)
[Em] Mês de entrada:1705
[Cu] Atualização por classe:170504
[Lr] Data última revisão:
170504
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:160908
[St] Status:MEDLINE
[do] DOI:10.1038/ja.2016.110


  4 / 142 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:27745736
[Au] Autor:Smith KP; Kirby JE
[Ad] Endereço:Department of Pathology, 330 Brookline Avenue - YA309, Beth Israel Deaconess Medical Center, Boston, MA, USA. Electronic address: kpsmith@bidmc.harvard.edu.
[Ti] Título:Evaluation of apramycin activity against carbapenem-resistant and -susceptible strains of Enterobacteriaceae.
[So] Source:Diagn Microbiol Infect Dis;86(4):439-441, 2016 Dec.
[Is] ISSN:1879-0070
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:We evaluated activity of apramycin, a non-ototoxic/non-nephrotoxic aminocyclitol against 141 clinical Enterobacteriaceae isolates, 51% of which were non-susceptible to carbapenems (CRE). Among CRE, 70.8% were apramycin susceptible, which compared favorably to aminoglycosides in current clinical use. Our data suggest that apramycin deserves further investigation as a repurposed, anti-CRE therapeutic.
[Mh] Termos MeSH primário: Antibacterianos/farmacologia
Enterobacteriaceae/efeitos dos fármacos
Nebramicina/análogos & derivados
Resistência beta-Lactâmica
[Mh] Termos MeSH secundário: Enterobacteriaceae/isolamento & purificação
Infecções por Enterobacteriaceae/microbiologia
Seres Humanos
Testes de Sensibilidade Microbiana
Nebramicina/farmacologia
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Anti-Bacterial Agents); 11048-13-8 (Nebramycin); 388K3TR36Z (apramycin)
[Em] Mês de entrada:1702
[Cu] Atualização por classe:170208
[Lr] Data última revisão:
170208
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:161018
[St] Status:MEDLINE


  5 / 142 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:27215463
[Au] Autor:Dasenaki ME; Michali CS; Thomaidis NS
[Ad] Endereço:Laboratory of Analytical Chemistry, Department of Chemistry, University of Athens, Panepistimiopolis Zographou, 15771 Athens, Greece.
[Ti] Título:Analysis of 76 veterinary pharmaceuticals from 13 classes including aminoglycosides in bovine muscle by hydrophilic interaction liquid chromatography-tandem mass spectrometry.
[So] Source:J Chromatogr A;1452:67-80, 2016 Jun 24.
[Is] ISSN:1873-3778
[Cp] País de publicação:Netherlands
[La] Idioma:eng
[Ab] Resumo:A multiresidue/multiclass method for the simultaneous determination of 76 veterinary drugs and pharmaceuticals in bovine muscle tissue has been developed and validated according to the requirements of European Commission Decision 2002/657/EC. The analytes belong in 13 different classes, including aminoglycoside antibiotics, whose different physicochemical properties (extremely polar character) render their simultaneous determination with other veterinary drugs quite problematic. The method combines a two-step extraction procedure (extraction with acetonitrile followed by an acidic aqueous buffer extraction) with hydrophilic interaction liquid chromatography-tandem mass spectrometry (HILIC-MS/MS) determination, allowing confirmation and quantification in a single chromatographic run. Further cleanup with solid phase extraction was performed using polymeric SPE cartridges. A thorough ionization study of aminoglycosides was performed in order to increase their sensitivity and significant differences in the abundance of the precursor ions of the analytes were revealed, depending on the composition of the mobile phase tested. Further gradient elution optimization and injection solvent optimization were performed for all target analytes.The method was validated according to the European Commission Decision 2002/657. Quantitative analysis was performed by means of standard addition calibration. Recoveries varied from 37.4% (bromhexine) to 106% (kanamycin) in the lowest validation level and 82% of the compounds showed recovery >70%. Detection capability (CCß) varied from 2.4 (salinomycin) to 1302 (apramycin) µgkg(-1).
[Mh] Termos MeSH primário: Aminoglicosídeos/análise
Antibacterianos/análise
Resíduos de Drogas/análise
Interações Hidrofóbicas e Hidrofílicas
Músculos/química
Espectrometria de Massas em Tandem/métodos
Drogas Veterinárias/análise
Drogas Veterinárias/classificação
[Mh] Termos MeSH secundário: Aminoglicosídeos/química
Animais
Antibacterianos/química
Bromoexina/análise
Calibragem
Bovinos
Cromatografia Líquida/métodos
Resíduos de Drogas/química
Canamicina/análise
Nebramicina/análogos & derivados
Nebramicina/análise
Piranos/análise
Extração em Fase Sólida
Drogas Veterinárias/química
[Pt] Tipo de publicação:JOURNAL ARTICLE; VALIDATION STUDIES
[Nm] Nome de substância:
0 (Aminoglycosides); 0 (Anti-Bacterial Agents); 0 (Pyrans); 0 (Veterinary Drugs); 11048-13-8 (Nebramycin); 388K3TR36Z (apramycin); 59-01-8 (Kanamycin); 62UXS86T64 (salinomycin); Q1J152VB1P (Bromhexine)
[Em] Mês de entrada:1612
[Cu] Atualização por classe:161230
[Lr] Data última revisão:
161230
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:160525
[St] Status:MEDLINE


  6 / 142 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:26928593
[Au] Autor:Vo DD; Tran TP; Staedel C; Benhida R; Darfeuille F; Di Giorgio A; Duca M
[Ad] Endereço:University of Nice Sophia Antipolis, Institute of Chemistry of Nice, UMR7272 CNRS, Parc Valrose, 06100, Nice, France.
[Ti] Título:Oncogenic MicroRNAs Biogenesis as a Drug Target: Structure-Activity Relationship Studies on New Aminoglycoside Conjugates.
[So] Source:Chemistry;22(15):5350-62, 2016 Apr 04.
[Is] ISSN:1521-3765
[Cp] País de publicação:Germany
[La] Idioma:eng
[Ab] Resumo:MicroRNAs (miRNAs) are a recently discovered category of small RNA molecules that regulate gene expression at the post-transcriptional level. Accumulating evidence indicates that miRNAs are aberrantly expressed in a variety of human cancers and that the inhibition of these oncogenic miRNAs could find application in the therapy of different types of cancer. Herein, we describe the synthesis and biological evaluation of new small-molecule drugs that target oncogenic miRNAs production. In particular, we chose to target two miRNAs (i.e., miRNA-372 and -373) implicated in various types of cancer, such as gastric cancer. Their precursors (pre-miRNAs) are overexpressed in cancer cells and lead to mature miRNAs after cleavage of their stem-loop structure by the enzyme Dicer in the cytoplasm. Some of the newly synthesized conjugates can inhibit Dicer processing of the targeted pre-miRNAs in vitro with increased efficacy relative to our previous results (D.D. Vo et al., ACS Chem. Biol. 2014, 9, 711-721) and, more importantly, to inhibit proliferations of adenocarcinoma gastric cancer (AGS) cells overexpressing these miRNAs, thus representing promising leads for future drug development.
[Mh] Termos MeSH primário: Aminoglicosídeos/química
MicroRNAs/antagonistas & inibidores
MicroRNAs/genética
Neoplasias Gástricas/química
[Mh] Termos MeSH secundário: Evolução Biológica
Sistemas de Liberação de Medicamentos
Seres Humanos
MicroRNAs/química
Modelos Moleculares
Nebramicina/análogos & derivados
Nebramicina/química
Neomicina/química
Neoplasias Gástricas/tratamento farmacológico
Neoplasias Gástricas/patologia
Relação Estrutura-Atividade
[Pt] Tipo de publicação:JOURNAL ARTICLE; RESEARCH SUPPORT, NON-U.S. GOV'T
[Nm] Nome de substância:
0 (Aminoglycosides); 0 (MicroRNAs); 11048-13-8 (Nebramycin); 1404-04-2 (Neomycin); 388K3TR36Z (apramycin)
[Em] Mês de entrada:1608
[Cu] Atualização por classe:160331
[Lr] Data última revisão:
160331
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:160302
[St] Status:MEDLINE
[do] DOI:10.1002/chem.201505094


  7 / 142 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
PubMed Central Texto completo
Texto completo
[PMID]:26739225
[Au] Autor:Herrero-Fresno A; Zachariasen C; Hansen MH; Nielsen A; Hendriksen RS; Nielsen SS; Olsen JE
[Ad] Endereço:Department of Veterinary Disease Biology, Faculty of Health and Medical Sciences, University of Copenhagen, Frederiksberg, Denmark. ahefr@sund.ku.dk.
[Ti] Título:Apramycin treatment affects selection and spread of a multidrug-resistant Escherichia coli strain able to colonize the human gut in the intestinal microbiota of pigs.
[So] Source:Vet Res;47:12, 2016 Jan 07.
[Is] ISSN:1297-9716
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:The effect of apramycin treatment on transfer and selection of an Escherichia coli strain (E. coli 912) in the intestine of pigs was analyzed through an in vivo experiment. The strain was sequenced and assigned to the sequence type ST101 and serotype O11. It carried resistance genes to apramycin/gentamicin, sulphonamide, tetracycline, hygromycin B, ß-lactams and streptomycin [aac(3)-IV, sul2, tet(X), aph(4), bla TEM-1 and strA/B], with all but tet(X) located on the same conjugative plasmid. Nineteen pigs were randomly allocated into two inoculation groups, one treated with apramycin (pen 2) and one non-treated (pen 3), along with a non-inoculated control group (pen 1). Two pigs of pen 2 and 3 were inoculated intragastrically with a rifampicin resistant variant of the strain. Apramycin treatment in pen 2 was initiated immediately after inoculation. Strain colonization was assessed in the feces from all pigs. E. coli 912 was shown to spread to non-inoculated pigs in both groups. The selective effect did not persist beyond 3 days post-treatment, and the strain was not detected from this time point in pen 2. We demonstrated that E. coli 912 was able to spread between pigs in the same pen irrespective of treatment, and apramycin treatment resulted in significantly higher counts compared to the non-treated group. This represents the first demonstration of how antimicrobial treatment affects spread of resistant bacteria in pig production. The use of apramycin may lead to enhanced spread of gentamicin-resistant E. coli. Since gentamicin is a first-choice drug for human bacteremia, this is of concern.
[Mh] Termos MeSH primário: Farmacorresistência Bacteriana Múltipla
Escherichia coli/efeitos dos fármacos
Intestinos/microbiologia
Nebramicina/análogos & derivados
Seleção Genética
Doenças dos Suínos/microbiologia
[Mh] Termos MeSH secundário: Animais
Antibacterianos/farmacologia
Derrame de Bactérias
Escherichia coli/fisiologia
Infecções por Escherichia coli/microbiologia
Infecções por Escherichia coli/transmissão
Infecções por Escherichia coli/veterinária
Fezes/microbiologia
Feminino
Seres Humanos
Masculino
Nebramicina/farmacologia
Suínos
Fatores de Tempo
Zoonoses
[Pt] Tipo de publicação:JOURNAL ARTICLE; RESEARCH SUPPORT, NON-U.S. GOV'T
[Nm] Nome de substância:
0 (Anti-Bacterial Agents); 11048-13-8 (Nebramycin); 388K3TR36Z (apramycin)
[Em] Mês de entrada:1610
[Cu] Atualização por classe:170220
[Lr] Data última revisão:
170220
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:160108
[St] Status:MEDLINE
[do] DOI:10.1186/s13567-015-0291-z


  8 / 142 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:26695285
[Au] Autor:Long Z; Guo Z; Liu X; Zhang Q; Liu X; Jin Y; Liang L; Li H; Wei J; Wu N
[Ad] Endereço:Thermofisher Scientific Corporation, Beijing 10080, China.
[Ti] Título:A sensitive non-derivatization method for apramycin and impurities analysis using hydrophilic interaction liquid chromatography and charged aerosol detection.
[So] Source:Talanta;146:423-9, 2016.
[Is] ISSN:1873-3573
[Cp] País de publicação:Netherlands
[La] Idioma:eng
[Ab] Resumo:A sensitive non-derivatization method was developed for the analysis of apramycin and impurites using hydrophilic interaction liquid chromatography (HILIC) and charged aerosol detection (CAD). Sample was pretreated with an effective SPE method (recovery >90%) to remove interference with apramycin impurities from sulfate, then analyzed with direct injection. Different chromatography modes of separation and choices of HILIC column were investigated in search of a direct analysis method. The HILIC-CAD method was optimized using a cysteine-bonded zwitterionic HILIC column and compared to the strong cation exchange-ultraviolet (SCX-UV) method with post-column derivatization recommended by the Chinese Pharmacopoeia (veterinary) 2010. The improved chromatographic resolution and peak shape with the HILIC-charged aerosol detection method allows for increase of sample load to 48.9 µg from only 2.8 µg with the SCX-UV approach. More than 16 impurities were detected with this method with improved resolution, and four were identified with MS, while only 7 impurities were detected with the SCX-UV method. Moreover, the current method has a good precision and reproducibility. The intra-day and inter-day of peak area variability was less than or equal to 4.760% RSD and 9.950%, respectively. The average limit of detection and quantization was 80 ng and 200 ng injected on the column, respectively. The overall results demonstrated that the presented method can be used as an alternative to SCX-UV method in the analysis of apramycin and impurities.
[Mh] Termos MeSH primário: Cromatografia Líquida/métodos
Interações Hidrofóbicas e Hidrofílicas
Nebramicina/análogos & derivados
[Mh] Termos MeSH secundário: Aerossóis
Métodos Analíticos de Preparação de Amostras
Limite de Detecção
Nebramicina/análise
Nebramicina/química
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Aerosols); 11048-13-8 (Nebramycin); 388K3TR36Z (apramycin)
[Em] Mês de entrada:1609
[Cu] Atualização por classe:151223
[Lr] Data última revisão:
151223
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:151224
[St] Status:MEDLINE


  9 / 142 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:25468903
[Au] Autor:Harmer CJ; Holt KE; Hall RM
[Ad] Endereço:School of Molecular Bioscience, The University of Sydney, Sydney, New South Wales, Australia christopher.harmer@sydney.edu.au.
[Ti] Título:A type 2 A/C2 plasmid carrying the aacC4 apramycin resistance gene and the erm(42) erythromycin resistance gene recovered from two Salmonella enterica serovars.
[So] Source:J Antimicrob Chemother;70(4):1021-5, 2015 Apr.
[Is] ISSN:1460-2091
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:OBJECTIVES: To determine the relationships between RepA/C2 plasmids carrying several antibiotic resistance genes found in isolates of Salmonella enterica serovars Ohio and Senftenberg from pigs. METHODS: Illumina HiSeq was used to sequence seven S. enterica isolates. BLAST searches identified relevant A/C2 plasmid contigs and contigs were assembled using PCR. RESULTS: Two serovar Ohio isolates were ST329 and the five Senftenberg isolates were ST210. The A/C2 plasmids recovered from the seven isolates belong to type 2 and contain two resistance islands. Their backbones are closely related, differing by five or fewer SNPs. The sul2-containing resistance island ARI-B is 19.9 kb and also contains the kanamycin and neomycin resistance gene aphA1, the tetracycline resistance gene tetA(D) and an erythromycin resistance gene, erm(42), not previously seen in A/C2 plasmids. A second 30.3 kb resistance island, RI-119, is in a unique location in the A/C2 backbone 8.2 kb downstream of rhs. RI-119 contained genes conferring resistance to apramycin, netilmicin and tobramycin (aacC4), hygromycin (hph), sulphonamides (sul1) and spectinomycin and streptomycin (aadA2). In one of the seven plasmids, this resistance region contained two IS26-mediated deletions. A discrete 5.7 kb segment containing the aacC4 and hph genes and bounded by IS26 on one side and the inverted repeat of Tn5393 on the other was identified. CONCLUSIONS: The presence of almost identical A/C2 plasmids in two serovars indicates a common origin. Type 2 A/C2 plasmids continue to evolve via addition of new resistance regions such as RI-119 and evolution of existing ones.
[Mh] Termos MeSH primário: Antibacterianos/farmacologia
Farmacorresistência Bacteriana
Eritromicina/farmacologia
Genes Bacterianos
Nebramicina/análogos & derivados
Plasmídeos/isolamento & purificação
Salmonella enterica/genética
[Mh] Termos MeSH secundário: Animais
DNA Helicases/genética
Evolução Molecular
Genoma Bacteriano
Dados de Sequência Molecular
Nebramicina/farmacologia
Plasmídeos/classificação
Salmonelose Animal/microbiologia
Salmonella enterica/efeitos dos fármacos
Salmonella enterica/isolamento & purificação
Análise de Sequência de DNA
Suínos
Doenças dos Suínos/microbiologia
[Pt] Tipo de publicação:JOURNAL ARTICLE; RESEARCH SUPPORT, NON-U.S. GOV'T
[Nm] Nome de substância:
0 (Anti-Bacterial Agents); 11048-13-8 (Nebramycin); 388K3TR36Z (apramycin); 63937KV33D (Erythromycin); EC 3.6.4.- (DNA Helicases)
[Em] Mês de entrada:1511
[Cu] Atualização por classe:150312
[Lr] Data última revisão:
150312
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:141204
[St] Status:MEDLINE
[do] DOI:10.1093/jac/dku489


  10 / 142 MEDLINE  
              first record previous record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:25403198
[Au] Autor:Jacquier V; Combes S; Oswald IP; Rogel-Gaillard C; Gidenne T
[Ad] Endereço:INRA, UMR 1388 Génétique, Physiologie et Systèmes d'Elevage, F-31326 Castanet-Tolosan, France Université de Toulouse INPT ENSAT, UMR 1388 Génétique, Physiologie et Systèmes d'Elevage, F-31326 Castanet-Tolosan, France Université de Toulouse INPT ENVT, UMR 1388 Génétique, Physiologie et Systèmes d'Ele
[Ti] Título:Early modulation of the cecal microbial activity in the young rabbit with rapidly fermentable fiber: impact on health and growth.
[So] Source:J Anim Sci;92(12):5551-9, 2014 Dec.
[Is] ISSN:1525-3163
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:This study aimed at comparing various diets predicted to induce different stimulations of the cecal microbial activity of the young rabbit fed ad libitum from 16 to 70 d of age: i) a diet enriched with rapidly fermentable fiber expected to stimulate the cecal microbial activity (RFF group); ii) a control diet with a standard composition (C group); iii) and the same control diet with tiamulin and apramycin antibiotics, expected to inhibit the microbial activity (C+AB group). A total of 398 rabbits were used from 42 litters and weaned at 28 d of age. An in vivo digestibility trial was performed on 36 rabbits of 42 to 46 d of age housed in individual metabolic cages. The feed intake and growth rates were lower in the RFF group compared with the C+AB group (-15% in ADFI and -11% in ADG, P<0.001), with a lower weight of -183 g at 70 d (P<0.001). No significant difference was found on ADG and final BW between the RFF and the C groups, but the RFF diet allowed a better G:F ratio at postweaning (P<0.01). The digestion of soluble fiber (total dietary fiber minus NDF) was greater for the RFF group. The C+AB diet had a positive effect on the postweaning morbidity rate (P<0.05) but did not affect the mortality rate and the health risk index (morbidity and mortality). Conversely, the RFF diet appeared to reduce the mortality rate compared with the C+AB diet, especially before 41 d of age. Concerning the cecal microbial activity, a supply of RFF in the diet increased the cecal VFA concentrations (+28% vs. C+AB and +22% vs. C, P<0.001) and lowered the pH. The VFA pattern was affected at 45 and 60 d, with a dominance of acetate in the RFF group (+4% vs. C+AB and C groups, P<0.001) instead of butyrate in the C+AB and C groups (-3.6% and -5% vs. C+AB and C, respectively, P<0.001). Antibiotics addition (C+AB group) reduced the VFA concentration, but only after weaning (-25% at 45 d of age) without changing the fermentation pattern. In conclusion, early intake of RFF in young rabbits stimulated the cecal microbial activity, and reduced the voluntary feed intake, leading to a reduced G:F ratio.
[Mh] Termos MeSH primário: Ração Animal/análise
Fenômenos Fisiológicos da Nutrição Animal
Ceco/microbiologia
Fibras na Dieta/farmacologia
Digestão/fisiologia
Microbiota/efeitos dos fármacos
Coelhos/crescimento & desenvolvimento
[Mh] Termos MeSH secundário: Fatores Etários
Animais
Antibacterianos/farmacologia
Ceco/efeitos dos fármacos
Dieta/veterinária
Fibras na Dieta/metabolismo
Digestão/efeitos dos fármacos
Diterpenos
Ingestão de Alimentos/efeitos dos fármacos
Ácidos Graxos/metabolismo
Fermentação/efeitos dos fármacos
Nebramicina/análogos & derivados
Coelhos/microbiologia
[Pt] Tipo de publicação:COMPARATIVE STUDY; JOURNAL ARTICLE; RANDOMIZED CONTROLLED TRIAL
[Nm] Nome de substância:
0 (Anti-Bacterial Agents); 0 (Dietary Fiber); 0 (Diterpenes); 0 (Fatty Acids); 11048-13-8 (Nebramycin); 388K3TR36Z (apramycin); E38WZ4U54R (tiamulin)
[Em] Mês de entrada:1510
[Cu] Atualização por classe:171116
[Lr] Data última revisão:
171116
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:141119
[St] Status:MEDLINE
[do] DOI:10.2527/jas.2014-7604



página 1 de 15 ir para página                         
   


Refinar a pesquisa
  Base de dados : MEDLINE Formulário avançado   

    Pesquisar no campo  
1  
2
3
 
           



Search engine: iAH v2.6 powered by WWWISIS

BIREME/OPAS/OMS - Centro Latino-Americano e do Caribe de Informação em Ciências da Saúde